Stay updated with breaking news from Deborah Elson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--May 23, 2024--
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Feb 28, 2024--
Published: May 11, 2021 - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 - WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the first q...